Opaganib

DRUG6 trials

Sponsors

RedHill Biopharma Limited, Medical University of South Carolina, Shaare Zedek Medical Center

Conditions

COVID-19Coronavirus InfectionsLung InfectionMultiple MyelomaProstate Cancer

Phase 1

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

TerminatedNCT02757326

RedHill Biopharma LimitedMultiple Myeloma

Start: 2016-12-13End: 2019-05-31Updated: 2021-06-18

Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen

WithdrawnNCT04502069

RedHill Biopharma LimitedCOVID-19, Lung Infection

Start: 2020-08-31End: 2021-06-30Updated: 2020-08-11

Phase 2

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

CompletedNCT04207255

Medical University of South CarolinaProstate Cancer

Start: 2020-03-27End: 2024-07-31Updated: 2024-09-25

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

CompletedNCT04414618

RedHill Biopharma LimitedCoronavirus Infections

Start: 2020-07-02End: 2020-12-23Updated: 2022-03-21

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

CompletedNCT04467840

RedHill Biopharma LimitedCOVID-19, Lung Infection

Start: 2020-08-21End: 2021-07-18Updated: 2025-07-31

Unknown Phase

Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19)

CompletedNCT04435106

Shaare Zedek Medical CenterCoronavirus Infections

Start: 2020-04-03End: 2020-05-15Updated: 2020-06-17

Related Papers

Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.

2022-12-0315 citations

Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255).

Journal of Clinical Oncology2021-02-203 citations

Combination Therapy Shows Synergistic Effect in Myeloma Treatment

Oncology Times2018-08-07